Foresite Capital Management IV, LLC Diversified Active

Name: Foresite Capital Management IV, LLC Q2 2022 13F Filing | 13F Explorer
Creator: Foresite Capital Management IV, LLC
Published: 2022-08-12

Location: West Hollywood, CA

CIK: 0001704132 · Show all filings

Period: Q2 2022 (← Previous) (Next →)

Filing Date: Aug 12, 2022

Total Value: $371M (100.0% shares, 0.0% debt)

Holdings (8)

— Kinnate Biopharma Inc. 32.8%

Value $122M Shares 9,671,643 Est. Cost $39.78 Unrealized —

— Lyell Immunopharma, Inc. 23.3%

Value $86.6M Shares 13,282,181 Est. Cost $16.24 Unrealized —

PHVS Pharvaris N.V. 19.3%

Value $71.76M Shares 3,246,926 Est. Cost $31.46 Unrealized -40.8%

ACRS Aclaris Therapeutics, Inc. 10.6%

Value $39.2M Shares 2,808,034 Est. Cost $15.18 Unrealized -7.7%

KURA Kura Oncology, Inc. 9.1%

Value $33.91M Shares 1,849,947 Est. Cost $20.39 Unrealized -29.4%

NRIX Nurix Therapeutics, Inc. 2.3%

Value $8.579M Shares 677,143 Est. Cost $25.20 Unrealized -55.0%

— Cymabay Therapeutics, Inc. 1.4%

Value $5.272M Shares 1,787,094 Est. Cost $3.49 Unrealized —

QSI Quantum-Si Incorporated 1.1%

Value $4.109M Shares 1,771,249 Est. Cost $10.48 Unrealized -63.4%

Ticker	Issuer	Shares	Value	%	Est. Cost	Unrealized	Class	CUSIP
—	Kinnate Biopharma Inc.	9,671,643	$122M	32.8%	$39.78	—	COM	49705R105
—	Lyell Immunopharma, Inc.	13,282,181	$86.6M	23.3%	$16.24	—	COM	55083R104
PHVS	Pharvaris N.V.	3,246,926	$71.76M	19.3%	$31.46	-40.8%	COM	N69605108
ACRS	Aclaris Therapeutics, Inc.	2,808,034	$39.2M	10.6%	$15.18	-7.7%	COM	00461U105
KURA	Kura Oncology, Inc.	1,849,947	$33.91M	9.1%	$20.39	-29.4%	COM	50127T109
NRIX	Nurix Therapeutics, Inc.	677,143	$8.579M	2.3%	$25.20	-55.0%	COM	67080M103
—	Cymabay Therapeutics, Inc.	1,787,094	$5.272M	1.4%	$3.49	—	COM	23257D103
QSI	Quantum-Si Incorporated	1,771,249	$4.109M	1.1%	$10.48	-63.4%	COM CL A	74765K105